Biosimilars: Opportunities and Challenges for Nurse Practitioners

Preconceived notions about biosimilars—a French experience

“…The patient knows that he receives a biologic medicine but is often not sufficiently informed of its biosimilar status, making this interchangeability almost invisible. This lack of information is also frequently observed in the field at the nursing staff level in day hospitals, who are not always aware of the changes and for whom the use of the international non-proprietary name (INN) no longer makes it possible to distinguish the different biologics [16]. This situation is less conceivable with biologics used subcutaneously, because the medical prescription is done by brand names, the delivery by the pharmacist of one well-identified box with a specific device, and the access to the information on websites.…”

Practical Strategies for Advanced Practitioners Streamlining the Integration of Oncology Biosimilar Therapies Into Practice

“…ADAs = anti-drug antibodies; AP = advanced practitioner; FDA = US Food and Drug Administration; NAbs = neutralizing antibodies; RP = reference product. Information from American Society of Clinical Oncology (2015) ; Blevins (2019); Chiu & Gilliland (2016) ; Christl (2018) ; Christl & Lim (2018) ; Cuellar et al (2019) ; Curigliano et al (2016) ; Demler (2018) ; FDA (2015, 2017b, 2019b, 2020b); Gabay (2017) ; Grampp & Ramanan (2015) ; Isaacs et al (2017) ; Kim et al (2020) ; Krishna & Nadler (2016) ; Lyman et al (2018) ; Markus et al (2017) ; Mayden et al (2015) ; McClellan et al (2019) ; McMahon Publishing (2013) ; NIH National Cancer Institute (2019) ; Pittman et al (2016, 2019); Schellekens et al (2016) ; Stanton (2017) ; Stebbing et al (2020) ; Thill et al (2019) ; Rumore et al (2016) ; Webster et al (2019) ; Welch (2017) ; van Brummelen et al (2016) .…”